MCID: PRL003
MIFTS: 44

Proliferative Glomerulonephritis

Categories: Nephrological diseases

Aliases & Classifications for Proliferative Glomerulonephritis

MalaCards integrated aliases for Proliferative Glomerulonephritis:

Name: Proliferative Glomerulonephritis 12 54 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4778
NCIt 49 C35281
SNOMED-CT 67 441815006
UMLS 71 C0235618

Summaries for Proliferative Glomerulonephritis

MalaCards based summary : Proliferative Glomerulonephritis is related to acute proliferative glomerulonephritis and mesangial proliferative glomerulonephritis. An important gene associated with Proliferative Glomerulonephritis is CXCL9 (C-X-C Motif Chemokine Ligand 9), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Azathioprine and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include kidney, monocytes and liver, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Proliferative Glomerulonephritis

Diseases in the Proliferative Glomerulonephritis family:

Acute Proliferative Glomerulonephritis

Diseases related to Proliferative Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 452)
# Related Disease Score Top Affiliating Genes
1 acute proliferative glomerulonephritis 34.9 MPO CCL2 C3
2 mesangial proliferative glomerulonephritis 32.5 THY1 TGFB1I1 PDGFD IL6 EDN1 CCR5
3 glomerulonephritis 31.1 MPO CR1 CFH CD55 CCN2 CCL2
4 cryoglobulinemia 30.9 IL6 IFNG CXCL9 CXCL10
5 dense deposit disease 30.8 CFH C3
6 c3 glomerulopathy 30.8 CFH C3
7 purpura 30.7 IL6 IL4 IFNG C3
8 vasculitis 30.7 MPO IL6 CCL2 C3
9 exanthem 30.6 MPO IL6 IFNG
10 relapsing polychondritis 30.5 IL6 IFNG CCL2
11 pyelonephritis 30.4 IL6 IFNG CXCL10 CCL2
12 genetic atypical hemolytic-uremic syndrome 30.4 CFH C3
13 hemolytic-uremic syndrome 30.4 CFH CD55 C3
14 brucellosis 30.3 MPO IL6 IL4 IFNG
15 lymphadenitis 30.2 IFNG CXCR3 CXCL9
16 aphthous stomatitis 30.2 IL6 IL4 IFNG
17 stomatitis 30.2 IL6 IL4 IFNG
18 leprosy 3 30.2 IL6 IL4 IFNG CXCL10
19 temporal arteritis 30.1 MPO IL6 IFNG CCL2
20 kidney disease 30.1 IL6 EDN1 CFH CCN2 CCL2 C3
21 hemolytic uremic syndrome, atypical 1 30.1 CR1 CFH CD55 C3
22 hepatitis a 30.1 IL4 IFNG CXCL10
23 hemoglobinuria 30.0 CR1 CD55 C3
24 crescentic glomerulonephritis 30.0 MPO CCR5 CCN2 CCL3 CCL2
25 myositis 30.0 IL6 IFNG CXCL10 CCL2
26 myeloma, multiple 30.0 IL6 IL4 IFNG CCL3 CCL2
27 crohn's disease 30.0 IL6 IL4 IFNG CCL2
28 castleman disease 29.9 IL6 IL4 IFNG CR1
29 pancytopenia 29.9 MPO IL6 IFNG CD55
30 q fever 29.9 IL6 IL4 IFNG CXCL9 CCL2
31 peripheral nervous system disease 29.8 IL6 IL4 IFNG CCL2
32 lymphopenia 29.8 IL6 IL4 IFNG CD55
33 myasthenia gravis 29.8 IL4 IFNG CR1 CD55
34 osteomyelitis 29.8 IL6 IL4 IFNG CXCL10 CCL2
35 hemolytic anemia 29.7 IL4 IFNG CR1 CFH CD55 C3
36 schistosomiasis 29.6 IL4 IFNG CCL3 CCL2
37 bacterial infectious disease 29.5 IL6 IFNG CXCL9 CCL3 CCL2
38 systemic scleroderma 29.4 IL6 IL4 IFNG EDN1 CCN2
39 leukemia, chronic lymphocytic 29.4 IL6 IL4 CXCR3 CR1 CD55 CCR5
40 respiratory failure 29.3 MPO IL6 EDN1 CXCL10
41 uveitis 29.3 IL6 IL4 IFNG CXCR3 CXCL10 CCR5
42 connective tissue disease 29.3 IL6 IL4 IFNG EDN1 CCN2
43 psoriasis 29.3 IL6 IL4 IFNG CXCR3 CXCL9 CXCL10
44 interstitial lung disease 29.3 IL6 IL4 IFNG EDN1 CXCL9 CXCL10
45 aspergillosis 29.3 IL6 IL4 IFNG CXCL10 CCL3
46 retinal detachment 29.2 IL6 IFNG EDN1 CXCL10 CCN2 CCL2
47 arthritis 29.1 IL6 IL4 IFNG CR1 CCL3 CCL2
48 proteasome-associated autoinflammatory syndrome 1 29.0 MPO IL6 IL4 IFNG CXCL10 CCL3
49 autoimmune disease 29.0 IL6 IL4 IFNG CXCR3 CXCL10 CD55
50 myocarditis 29.0 IL6 IL4 IFNG CD55 CCL3 CCL2

Graphical network of the top 20 diseases related to Proliferative Glomerulonephritis:



Diseases related to Proliferative Glomerulonephritis

Symptoms & Phenotypes for Proliferative Glomerulonephritis

MGI Mouse Phenotypes related to Proliferative Glomerulonephritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 C3 CCN2 CCR5 CD55 CFH CXCL10
2 cardiovascular system MP:0005385 10.18 C3 CCN2 CCR5 CFH CXCL10 CXCR3
3 hematopoietic system MP:0005397 10.11 C3 CCR5 CD55 CFH CXCL10 CXCR3
4 immune system MP:0005387 10.03 C3 CCL2 CCR5 CD55 CFH CXCL10
5 muscle MP:0005369 9.81 C3 CCR5 CD55 CFH EDN1 IFNG
6 normal MP:0002873 9.61 C3 CCN2 CFH CXCR3 EDN1 IFNG
7 renal/urinary system MP:0005367 9.23 C3 CD55 CFH CXCR3 EDN1 IFNG

Drugs & Therapeutics for Proliferative Glomerulonephritis

Drugs for Proliferative Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 3 446-86-6 2265
2
Mycophenolic acid Approved Phase 2, Phase 3 24280-93-1 446541
3
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
4
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
5
Abatacept Approved Phase 2, Phase 3 332348-12-6 10237
6
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
7
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
8
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
9 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
10
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
11 Antimetabolites Phase 3
12 Antitubercular Agents Phase 2, Phase 3
13 Immunologic Factors Phase 2, Phase 3
14 Anti-Bacterial Agents Phase 2, Phase 3
15 Anti-Infective Agents Phase 2, Phase 3
16 Immunosuppressive Agents Phase 2, Phase 3
17 Antibiotics, Antitubercular Phase 2, Phase 3
18 Antirheumatic Agents Phase 2, Phase 3
19 Pharmaceutical Solutions Phase 2, Phase 3
20 Hormones Phase 2, Phase 3
21 Methylprednisolone Acetate Phase 2, Phase 3
22 Antineoplastic Agents, Hormonal Phase 2, Phase 3
23 glucocorticoids Phase 2, Phase 3
24 Hormone Antagonists Phase 2, Phase 3
25 Anti-Inflammatory Agents Phase 2, Phase 3
26
Daratumumab Approved Phase 2 945721-28-8
27
Tacrolimus Approved, Investigational Phase 1 104987-11-3 445643 439492 6473866
28
Triamcinolone Approved, Vet_approved Phase 1 124-94-7 31307
29
tannic acid Approved Phase 1 1401-55-4
30
Benzocaine Approved, Investigational Phase 1 94-09-7, 1994-09-7 2337
31
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
32
Hydrocortisone Approved, Vet_approved Phase 1 50-23-7 5754
33
Promethazine Approved, Investigational Phase 1 60-87-7 4927
34
Acetaminophen Approved Phase 1 103-90-2 1983
35
Hydrocortisone acetate Approved, Vet_approved Phase 1 50-03-3
36
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
37
Diphenhydramine Approved, Investigational Phase 1 58-73-1, 147-24-0 3100
38
alemtuzumab Approved, Investigational Phase 1 216503-57-0
39 Alkylating Agents Phase 1
40 Triamcinolone diacetate Phase 1
41 Triamcinolone hexacetonide Phase 1
42 Calcineurin Inhibitors Phase 1
43 triamcinolone acetonide Phase 1
44 Hydrocortisone 17-butyrate 21-propionate Phase 1
45 diuretics Phase 1
46 Hydrocortisone hemisuccinate Phase 1
47 Antineoplastic Agents, Immunological Phase 1
48 Antigen-Antibody Complex Phase 1
49
Leflunomide Approved, Investigational 75706-12-6 3899

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomized Multicenter Trial Comparing Mycophenolate Mofetil and Azathioprine as Remission-maintaining Treatment for Proliferative Lupus Glomerulonephritis. The MAINTAIN Nephritis Trial. Completed NCT00204022 Phase 3 Mycophenolate mofetil;Azathioprine
2 A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects With Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE) Terminated NCT00430677 Phase 2, Phase 3 Corticosteroids (prednisone or prednisolone);Abatacept;Abatacept;Mycophenolate mofetil (MMF);Abatacept
3 Immune Ablation and Hematopoietic Stem Cell Support in Patients With Poor Prognostic Indicators and Systemic Lupus Erythematosus:A Phase II Study Completed NCT00271934 Phase 2
4 Single-center Phase 2 Open-label Trial Evaluating Efficacy and Safety of Daratumumab in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immune Deposits and C3 Glomerulopathy Associated With Monoclonal Gammopathy Active, not recruiting NCT03095118 Phase 2 Daratumumab
5 Tacrolimus Versus Cyclophosphamide as Treatment for Diffuse Proliferative or Membranous Lupus Nephritis: Prospective Cohort Study Completed NCT01207297 Phase 1 Tacrolimus;cyclophosphamide
6 Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Severe Autoimmune Diseases Terminated NCT00849745 Phase 1
7 A Randomized Multicenter Trial Comparing Leflunomide and Azathioprine as Remission-Maintaining Treatment for Proliferative Lupus Glomerulonephritis. Unknown status NCT01172002 Leflunomide;Azathioprine
8 Clinical Significance of Assesment of Serum miRNA-30a in Childhood Nephrotic Syndrome Unknown status NCT03235128

Search NIH Clinical Center for Proliferative Glomerulonephritis

Genetic Tests for Proliferative Glomerulonephritis

Anatomical Context for Proliferative Glomerulonephritis

MalaCards organs/tissues related to Proliferative Glomerulonephritis:

40
Kidney, Monocytes, Liver, T Cells, Endothelial, Neutrophil, B Cells

Publications for Proliferative Glomerulonephritis

Articles related to Proliferative Glomerulonephritis:

(show top 50) (show all 2408)
# Title Authors PMID Year
1
[Expression of MCP-1 in renal tissues of patients with IgA nephropathy]. 61 54
19893256 2009
2
Characterization of kidney lesions in Indian adults: towards a renal biopsy registry. 54 61
16736422 2006
3
High endothelial venule-like vessels in the interstitial lesions of human glomerulonephritis. 54 61
11919403 2002
4
IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. 61 54
11752021 2002
5
Renal involvement in Adamantiades-Behçet's disease. Case report and review of the literature. 54 61
11760401 2001
6
Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. 61 54
10589690 1999
7
Successful treatment of adult-onset Henoch-Schönlein purpura nephritis with high-dose immunoglobulins. 61 54
10361914 1999
8
Significance of P-selectin expression in human glomerulonephritis. 61 54
9594207 1997
9
Increased mRNA expression of metalloproteinase-9 in peripheral blood monocytes from patients with immunoglobulin A nephropathy. 54 61
8712219 1996
10
Clinicopathologic Assessment of Monoclonal Immunoglobulin-associated Renal Disease in the Kidney Allograft: A Retrospective Study and Review of the Literature. 61
31634325 2020
11
IL-17 aggravates renal injury by promoting podocyte injury in children with primary nephrotic syndrome. 61
32537005 2020
12
Phenotypic spectrum and antialbuminuric response to angiotensin converting enzyme inhibitor and angiotensin receptor blocker therapy in pediatric Dent disease. 61
32495484 2020
13
Clinicopathological characteristics and outcome of patients with fibrillary glomerulonephritis: DNAJB9 is a valuable histologic marker. 61
32557205 2020
14
Epidemiological and clinical characteristics and outcome of monoclonal gammopathy of renal significance-related lesions in Latin America. 61
31825549 2020
15
KM55 Monoclonal Antibody and IgA Variant of Proliferative Glomerulonephritis With Monoclonal Ig Deposits. 61
32518879 2020
16
Clone-directed therapy for proliferative glomerulonephritis with monoclonal immunoglobulin depositions: is it always necessary? : Two case reports and literature review. 61
32221859 2020
17
Spectrum and prognosis of renal histopathological lesions in 56 Chinese patients with rheumatoid arthritis with renal involvement. 61
32048072 2020
18
Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report. 61
32361703 2020
19
Complement Deficiencies Result in Surrogate Pathways of Complement Activation in Novel Polygenic Lupus-like Models of Kidney Injury. 61
32238460 2020
20
An update to the pathogenesis for monoclonal gammopathy of renal significance. 61
32199132 2020
21
Ion-Channel modulator TH1177 reduces glomerular injury and serum creatinine in chronic mesangial proliferative disease in rats. 61
32429914 2020
22
Clinicopathologic features of infection-related glomerulonephritis with IgA deposits: a French Nationwide study. 61
32460869 2020
23
Treatment-resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury? 61
32447506 2020
24
A case of proliferative glomerulonephritis with immunoglobulin A1-lambda deposits successfully treated by chemotherapy. 61
32350770 2020
25
Prevention of parvovirus B19-induced repetitive acute kidney failure by subcutaneous immunoglobulins. 61
31605404 2020
26
Macrophage migration inhibitory factor regulates integrin-β1 and cyclin D1 expression via ERK pathway in podocytes. 61
31986415 2020
27
Renal pathologic spectrum and clinical outcome of monoclonal gammopathy of renal significance: A large retrospective case series study from a single institute in China. 61
31301197 2020
28
[A report of six TAFRO syndrome: clinical characteristics, diagnosis and treatment analysis]. 61
32164119 2020
29
Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis. 61
32355799 2020
30
Case report on mesangial proliferative glomerulonephritis with multicentric Castleman's disease: Approach to the onset mechanism of immunoglobulin A nephropathy. 61
31978558 2020
31
Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone. 61
32001067 2020
32
Rare case of post-varicella membranoproliferative glomerulonephritis presenting with massive proteinuria. 61
32169983 2020
33
Increased sMer, but not sAxl, sTyro3, and Gas6 relate with active disease in juvenile systemic lupus erythematosus. 61
31655933 2020
34
Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits without Conspicuous Mesangial Proliferation, Complicated with Squamous Cell Lung Carcinoma. 61
31611527 2020
35
TLR2 Expression on Select Lymphocyte Subsets as a New Marker in Glomerulonephritis. 61
32079183 2020
36
Successful simultaneous liver-kidney transplantation for renal failure associated with hereditary complement C3 deficiency. 61
31970896 2020
37
HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis. 61
31911409 2020
38
Reply to Comment on "An Unusual Case of Acquired Angioedema and Monoclonal Gammopathy of Renal Significance in a Middle-Aged Caucasian Female". 61
32493071 2020
39
Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone. 61
31391391 2019
40
Patterns of renal pathology in Chinese patients with systemic sclerosis undergoing renal biopsy at a tertiary medical center. 61
31878823 2019
41
TGF-β1 inhibits the autophagy of podocytes by activating mTORC1 in IgA nephropathy. 61
31600491 2019
42
[Acute renal failure and rare severe complication of systemic steroid treatment in a 73-year-old woman]. 61
31511906 2019
43
Bevacizumab-induced immunoglobulin A vasculitis with nephritis: A case report. 61
31702653 2019
44
HIV-associated Immune Complex Kidney Disease with C3-dominant Deposition Induced by HIV Infection after Treatment of IgA Nephropathy. 61
31243235 2019
45
The effectiveness of chitosan-mediated silencing of PDGF-B and PDGFR-β in the mesangial proliferative glomerulonephritis therapy. 61
31265815 2019
46
Nephrotic syndrome: immunological mechanisms. 61
31630708 2019
47
Monoclonal Gammopathy of Renal Significance and its Associated Experimental Models. 61
31471332 2019
48
PC-1 NF suppresses high glucose-stimulated inflammation and extracellular matrix accumulation in glomerular mesangial cells via the Wnt/β-catenin signaling. 61
31410160 2019
49
The role of transcriptional factor D-site-binding protein in circadian CCL2 gene expression in anti-Thy1 nephritis. 61
29568121 2019
50
Urine macrophages reflect kidney macrophage content during acute tubular interstitial and glomerular injury. 61
31212026 2019

Variations for Proliferative Glomerulonephritis

Expression for Proliferative Glomerulonephritis

Search GEO for disease gene expression data for Proliferative Glomerulonephritis.

Pathways for Proliferative Glomerulonephritis

Pathways related to Proliferative Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 SIGLEC1 MPO IL6 IL4 IFNG CXCL10
2
Show member pathways
13.76 TGFB1I1 PDGFD IL6 IL4 CXCR3 CXCL9
3
Show member pathways
13.64 IL6 IL4 IFNG EDN1 CXCR3 CXCL9
4
Show member pathways
13.34 IL6 IL4 IFNG CXCL10 CCR5 CCL3
5
Show member pathways
13.25 PDGFD IL6 IL4 CXCR3 CXCL9 CXCL10
6
Show member pathways
13.03 IL6 IFNG CXCL9 CXCL10 CCL3 CCL2
7
Show member pathways
13.02 PDGFD IL6 IL4 CXCR3 CXCL9 CXCL10
8
Show member pathways
12.85 IL6 IL4 IFNG CXCL9 CD55 C3
9
Show member pathways
12.81 TGFB1I1 CXCR3 CXCL9 CXCL10 CCR5 CCL3
10
Show member pathways
12.59 MPO IL6 IFNG CXCL9 CCL2
11 12.56 MPO IL4 IFNG CXCL10 CCL2
12
Show member pathways
12.31 IL6 IL4 IFNG CXCL10 CCL2
13
Show member pathways
12.3 MPO IL6 IL4 IFNG CCL2
14
Show member pathways
12.27 PDGFD IL6 IL4 IFNG CCN2
15 12.23 IL6 IFNG CR1 C3
16
Show member pathways
12.21 IL4 IFNG CR1 CCR5 C3
17
Show member pathways
12.19 IL6 IL4 IFNG CXCL10
18
Show member pathways
12.17 CR1 CFH CD55 C3
19
Show member pathways
12.12 CR1 CFH CD55 C3
20 12.11 CR1 CFH CD55 C3
21
Show member pathways
12.03 IL6 CXCR3 CXCL9 CXCL10 CCR5 CCL3
22
Show member pathways
11.98 IL4 IFNG CCR5 CCL3
23 11.96 IL6 EDN1 CXCL10 CCL2
24 11.93 IL6 IL4 IFNG CXCL10 CCL2
25 11.9 THY1 MPO IL6 IL4 IFNG
26 11.89 IL6 IL4 CR1 CD55
27 11.85 IL6 IFNG CCL3 CCL2
28
Show member pathways
11.83 IL6 IL4 IFNG
29 11.77 IL6 IL4 IFNG
30 11.72 THY1 IL6 IFNG
31 11.62 THY1 IL4 IFNG CXCR3 CCL3
32 11.61 IL6 CR1 C3
33 11.49 IL6 IFNG CR1 CCL2
34 11.46 THY1 MPO IL6 CCN2
35 11.39 IFNG CXCL9 CXCL10
36 11.35 CXCR3 CXCL9 CXCL10
37 11.31 IL6 IL4 IFNG
38 11.26 IL6 IL4 IFNG
39 11.23 IL6 IL4 EDN1 CCN2 CCL3 CCL2
40 10.9 MPO CCL3 CCL2
41 10.87 PDGFD IL6 IL4 CXCL9 CXCL10 CCN2
42 10.79 IL6 IL4 CXCL10 CCR5 CCL3 CCL2
43 10.77 IL6 IL4

GO Terms for Proliferative Glomerulonephritis

Cellular components related to Proliferative Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.9 THY1 MPO IL6 EDN1 CXCR3 CXCL9
2 extracellular space GO:0005615 9.77 PDGFD MPO IL6 IL4 IFNG EDN1
3 cell surface GO:0009986 9.73 THY1 CXCR3 CR1 CD55 CCR5 C3
4 external side of plasma membrane GO:0009897 9.72 THY1 CXCR3 CXCL9 CXCL10 CCR5
5 extracellular region GO:0005576 9.53 THY1 SIGLEC1 PDGFD MPO IL6 IL4

Biological processes related to Proliferative Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 IL6 IL4 CXCR3 CXCL9 CXCL10 CCR5
2 G protein-coupled receptor signaling pathway GO:0007186 10.16 EDN1 CXCR3 CXCL9 CXCL10 CCR5 CCL3
3 cell adhesion GO:0007155 10.09 THY1 TGFB1I1 SIGLEC1 CXCR3 CCN2 CCL2
4 positive regulation of gene expression GO:0010628 10.08 IL6 IL4 IFNG CCN2 CCL3
5 positive regulation of cell proliferation GO:0008284 10.02 PDGFD IL6 IL4 IFNG EDN1 CXCL10
6 angiogenesis GO:0001525 9.99 THY1 CXCR3 CCN2 CCL2
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 PDGFD CCN2 CCL3 CCL2
8 defense response to virus GO:0051607 9.96 IL6 IFNG CXCL9 CXCL10
9 positive regulation of cell migration GO:0030335 9.95 PDGFD IL4 EDN1 CXCL10 CCL3
10 cell surface receptor signaling pathway GO:0007166 9.91 IFNG EDN1 CXCR3 CXCL10 CCR5 CCL2
11 defense response GO:0006952 9.9 MPO CXCL9 CXCL10 CCR5
12 positive regulation of cytosolic calcium ion concentration GO:0007204 9.89 EDN1 CXCR3 CD55 CCR5
13 cellular response to lipopolysaccharide GO:0071222 9.89 IL6 CXCL9 CXCL10 CCR5 CCL2
14 response to bacterium GO:0009617 9.88 CXCL9 CXCL10 CCL2 C3
15 regulation of complement activation GO:0030449 9.88 CR1 CFH CD55 C3
16 cytokine-mediated signaling pathway GO:0019221 9.88 IL6 IL4 CXCL10 CCR5 CCL3 CCL2
17 cellular response to interleukin-1 GO:0071347 9.86 EDN1 CCL3 CCL2
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IL6 IL4 IFNG
19 cell-cell signaling GO:0007267 9.85 THY1 EDN1 CXCL9 CXCL10 CCR5 CCL3
20 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 PDGFD IL6 EDN1
21 cell chemotaxis GO:0060326 9.83 CXCR3 CCR5 CCL3 CCL2
22 humoral immune response GO:0006959 9.81 IL6 IFNG CCL2
23 calcium-mediated signaling GO:0019722 9.81 EDN1 CXCR3 CCR5 CCL3
24 monocyte chemotaxis GO:0002548 9.78 IL6 CCL3 CCL2
25 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 9.74 THY1 CXCL9 CXCL10
26 chemotaxis GO:0006935 9.73 CXCR3 CXCL9 CXCL10 CCR5 CCL3 CCL2
27 neutrophil chemotaxis GO:0030593 9.72 EDN1 CXCL9 CXCL10 CCL3 CCL2
28 positive regulation of chemokine biosynthetic process GO:0045080 9.69 IL4 IFNG
29 complement activation, alternative pathway GO:0006957 9.69 CFH C3
30 response to cholesterol GO:0070723 9.68 CCR5 CCL3
31 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 IL4 IFNG
32 signaling GO:0023052 9.67 CCR5 CCL3
33 positive regulation of receptor biosynthetic process GO:0010870 9.67 IFNG EDN1
34 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0014808 9.66 CCR5 CCL3
35 positive regulation of NMDA glutamate receptor activity GO:1904783 9.65 IFNG CCL2
36 regulation of complement-dependent cytotoxicity GO:1903659 9.64 CFH CD55
37 positive regulation of apoptotic cell clearance GO:2000427 9.63 CCL2 C3
38 astrocyte cell migration GO:0043615 9.63 CCL3 CCL2
39 T cell chemotaxis GO:0010818 9.63 CXCR3 CXCL10 CCL3
40 chemokine-mediated signaling pathway GO:0070098 9.63 CXCR3 CXCL9 CXCL10 CCR5 CCL3 CCL2
41 positive regulation of cellular respiration GO:1901857 9.62 IL4 IFNG
42 neuroinflammatory response GO:0150076 9.62 IL4 IFNG
43 inflammatory response GO:0006954 9.61 SIGLEC1 IL6 CXCR3 CXCL9 CXCL10 CCR5
44 immune response GO:0006955 9.32 IL6 IL4 IFNG CXCR3 CXCL9 CXCL10

Molecular functions related to Proliferative Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.62 MPO CXCL10 CFH CCN2
2 virus receptor activity GO:0001618 9.54 CR1 CD55 CCR5
3 growth factor activity GO:0008083 9.46 PDGFD IL6 IL4 CCN2
4 CXCR3 chemokine receptor binding GO:0048248 9.26 CXCL9 CXCL10
5 chemokine activity GO:0008009 9.26 CXCL9 CXCL10 CCL3 CCL2
6 cytokine activity GO:0005125 9.23 IL6 IL4 IFNG EDN1 CXCL9 CXCL10

Sources for Proliferative Glomerulonephritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....